Onglyza licence extended for use in combination with insulin

Onglyza (saxagliptin) can now be prescribed in combination with insulin for adults with type 2 diabetes, with or without metformin, when diet and exercise plus insulin alone do not provide adequate glycaemic control.

In a randomised, double-blind, placebo-controlled study (n=455), saxagliptin added to insulin therapy (with or without metformin) in patients with inadequate glycaemic control significantly reduced HbA1c and postprandial glucose levels compared with placebo at week 24. In an extension of the initial study, saxagliptin maintained the reduction in HbA1c levels at week 52 compared with placebo.

View Onglyza drug record

Further information: BMS/AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

News in brief - October 2013

News in brief - October 2013

Other new launches, licence changes and updates relevant...

Onglyza approved for triple oral therapy

Onglyza approved for triple oral therapy

Onglyza (saxagliptin) can now be used in combination...

Licence extensions for linagliptin and vildagliptin

Licence extensions for linagliptin and vildagliptin

The dipeptidyl peptidase 4 (DPP4) inhibitors linagliptin...

Galvus licensed for use in renal impairment

Galvus licensed for use in renal impairment

Galvus (vildagliptin) is now suitable for use with...

Onglyza approved for use in renal impairment

Onglyza approved for use in renal impairment

The licence for Onglyza (saxagliptin) has been extended...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases